Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS) today announced that it is initiating a single global pivotal Phase 3 clinical study (Violet ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Marinus Pharmaceuticals (MRNS) PT Raised to $24.50 at Ladenburg ThalmannMarch 6, 2019 1:35 PM Marinus Pharmaceuticals Initiates Phase 3 Study in Children with PCDH19-Related EpilepsyMarch 6, 2019 7:30 AM Pre-Open Stock Movers 03/05: (CTRP) (TGT) (LB) Higher; (AFH) (ADMS) (HOLX) Lower (more...)March 5, 2019 9:24 AM UPDATE: Jefferies Starts Marinus Pharmaceuticals (MRNS) at Buy ahead of Key Near-Term EventsMarch 5, 2019 1:14 AM